Home | Hindi | Kabir | Poetry | Workshop | BoloKids | Bolography | Writers | Contribute | Search | Contact                                                    Shop Online 

  Today's News

 

        Advertise on Boloji

Channels
In Focus

Analysis  
Bolography  
Cartoons
Environment 
Opinion 

Columns
 Business
 My Word 
 PlainSpeak 
 Random Thoughts 
Our Heritage

 Architecture
 Astrology
 Ayurveda
 Buddhism
 Cinema 
 Culture
 Dances 
 Festivals
 Hinduism
 History  
 People  
 Places 
 Sikhism
 Spirituality 
 Vastu 
 Vithika  

Society & Lifestyle

 Family Matters 
 Health
 Parenting
 Perspective 
 Recipes
 Society
 Teens 
 Women 

Creative Writings

Book Reviews
Ghalib's Corner
Humor
Individuality
Jagoji
Literary Shelf 
Love Letters  
Memoirs
Musings
Ramblings
Stories
Travelogues 

Computing
  General Articles
 
CC++ 
  Flash 
  Internet Security 
 
Java 
 
Linux     
  Networking  

June 14, 2007 
India's Biotech Exports Reach
$1.2 bn in 2006-07

New Delhi
Revenues from India's biotech industry exports grew by 47 percent to reach $1.2 billion in the financial year ending March 2007, according to a survey.

The leading pharma companies, which contributed almost 27 percent of the industry revenue, are Serum Institute, Biocon and Panacea Biotec, according to the survey conducted by BioSpectrum, a journal published by the CyberMedia Group, along with Association of Biotechnology Led Enterprises (ABLE).

The industry introduced more than a dozen new products along with several new transgenic cottonseeds for the bio-agri sector.

According to the survey, as much as 400 firms would earn revenues of about $5 billion by 2010, bringing almost 100 biotech products in the market.

The biopharma segment, accounting for over two-thirds of the industry, reported sales of Rs.59.73 billion, representing a growth of 27 percent. The bioservices sector registered 53 percent growth, the bioagri sector 55 percent, and the bioinformatics and bioindustrial sectors recorded growth of 21 percent and 5 percent respectively.

Last year witnessed numerous mergers and acquisitions in this sector with Pune-based Serum Institute picking up a 14 percent stake in Britain-based Lipoxen focussing on developing biologicals, vaccines and oncology drugs.

Biocon's Syngene tied up with Bristol-Myers Squibb to provide research and development services for discovery and early drug development. 

IANS | June 14, 2007  

Top





 

 Analysis | Architecture | Astrology | Ayurveda | Book Reviews | Buddhism | Cartoons | Cinema | Computing | Culture | Dances
Environment | Fables | Family Matters | Festivals | Hinduism | Health | History | Home Remedies | Humor | Individuality | Jagoji
Literary Shelf | Memoirs | Musings | Opinion | Parenting | Perspective | Photo Essays | Places | Ramblings
Random Thoughts | Recipes | Sikhism | Society | Spirituality | Stories | Teens | Travelogues | Vastu | Vithika | Women

 Home | News | समाचार | Kabir | Poetry | Workshop | BoloKids | Bolography | Writers | Contribute | Search | Contact | Shop 


Boloji.com is owned and managed by Boloji Media Inc
Privacy Policy | Disclaimer
No part of this Internet site may be reproduced without prior written permission of the copyright holder.